#1 Clinical Trials Search in Europe

Cisatracurium Besilate

Cisatracurium Besilate is a neuromuscular blocking agent being studied in various clinical trials for its potential benefits in critical care settings and anesthesia procedures. This article explores the ongoing research into its use for conditions such as acute respiratory distress syndrome (ARDS), intracranial hypertension, and the prevention of muscle fasciculations during anesthesia induction. We’ll examine how researchers are investigating the drug’s effects on patient outcomes, respiratory mechanics, and overall safety profile.

Table of Contents

What is Cisatracurium Besilate?

Cisatracurium Besilate, also known by its brand name Nimbex, is a medication classified as a neuromuscular blocking agent (NMBA)[1]. It belongs to a specific group of NMBAs called nondepolarizing neuromuscular blockers. This medication is primarily used in medical settings, particularly during surgeries and in intensive care units (ICUs), to cause temporary muscle paralysis[2].

Medical Uses

Cisatracurium Besilate is used in various medical scenarios, including:

  • Facilitating Endotracheal Intubation: It helps relax the muscles of the throat, making it easier for doctors to insert a breathing tube during general anesthesia[3].
  • Mechanical Ventilation: In critically ill patients, especially those with Acute Respiratory Distress Syndrome (ARDS), cisatracurium is used to improve patient-ventilator synchrony and facilitate lung-protective ventilation strategies[2].
  • Managing Intracranial Hypertension: In patients with severe traumatic brain injury, cisatracurium may be used to help control increased pressure inside the skull[4].
  • Preventing Muscle Fasciculations: When used before another muscle relaxant called succinylcholine, cisatracurium can help prevent involuntary muscle twitches[5].

How Cisatracurium Besilate Works

Cisatracurium Besilate works by blocking the communication between nerves and muscles. Specifically, it prevents a chemical called acetylcholine from binding to receptors on muscle cells. This interruption in communication results in temporary muscle paralysis[1].

The effects of cisatracurium are reversible, meaning that muscle function returns once the medication wears off or is counteracted by other drugs. This characteristic makes it useful for controlled muscle relaxation during medical procedures[3].

Administration and Dosage

Cisatracurium Besilate is typically administered intravenously (through a vein) by healthcare professionals in controlled settings such as operating rooms or intensive care units. The dosage can vary depending on the specific medical situation and patient characteristics[1].

In some cases, cisatracurium is given as a single dose, while in others, it may be administered as a continuous infusion. For example:

  • For facilitating endotracheal intubation, a single dose of 0.1-0.2 mg/kg might be used[3].
  • In critically ill patients with ARDS, a continuous infusion of 1-3 mcg/kg/min might be administered[2].

The depth and duration of muscle relaxation are carefully monitored using specialized equipment to ensure patient safety and optimal effect[6].

Side Effects and Precautions

While cisatracurium is generally considered safe when used appropriately, it can cause side effects. Some potential side effects include:

  • Prolonged muscle weakness: In some cases, the effects of cisatracurium may last longer than intended, leading to residual muscle weakness after a procedure[7].
  • Allergic reactions: Although rare, some patients may experience allergic reactions to cisatracurium[2].
  • Cardiovascular effects: Cisatracurium may cause changes in heart rate or blood pressure in some patients[2].

It’s important to note that cisatracurium is used under close medical supervision, and healthcare providers are trained to manage any potential side effects promptly[1].

Ongoing Research

Researchers continue to study cisatracurium to better understand its effects and optimize its use in various medical scenarios. Some areas of ongoing research include:

  • Optimal dosing in critically ill patients: Studies are investigating the most effective dosing strategies for patients in intensive care units[1].
  • Use in specific patient populations: Researchers are exploring how cisatracurium affects different age groups and patients with various medical conditions[5].
  • Comparison with other neuromuscular blocking agents: Studies are comparing cisatracurium to other similar medications to determine which might be most beneficial in different clinical scenarios[7].

These ongoing studies aim to improve patient care and outcomes by refining the use of cisatracurium in medical practice[6].

Aspect Details
Primary Uses in Trials Treatment of ARDS, management of intracranial hypertension, prevention of fasciculations during anesthesia
Potential Benefits Improved oxygenation, reduced mortality in ARDS, better patient-ventilator synchrony, facilitation of lung-protective ventilation
Key Outcome Measures Mortality rates, duration of mechanical ventilation, length of hospital stay, changes in intracranial pressure, respiratory mechanics
Dosing Strategies Weight-based dosing, titration based on patient response, investigation of optimal doses for specific scenarios
Safety Monitoring Cardiovascular complications, pulmonary issues, renal problems, critical illness neuromyopathy
Ongoing Research Focus Pharmacokinetics and pharmacodynamics in critically ill patients, optimal depth of neuromuscular blockade, effects on respiratory mechanics

FAQ

  • What is Cisatracurium Besilate used for in clinical trials? Cisatracurium Besilate is being studied for various uses in clinical trials, including treatment of acute respiratory distress syndrome (ARDS), management of intracranial hypertension in traumatic brain injury patients, prevention of muscle fasciculations during anesthesia induction, and its effects on respiratory mechanics in critically ill patients.
  • How might Cisatracurium Besilate benefit ARDS patients? Studies suggest that Cisatracurium Besilate may help improve oxygenation in ARDS patients, reduce mortality rates, and facilitate lung-protective ventilation by improving patient-ventilator synchrony and reducing barotrauma.
  • What are the potential side effects of Cisatracurium Besilate? While specific side effects vary between studies, researchers are monitoring for potential cardiovascular complications, pulmonary issues, renal problems, and the incidence of critical illness neuromyopathy. The drug's impact on muscle function and recovery time is also being closely observed.
  • How is the appropriate dose of Cisatracurium Besilate determined in clinical trials? Dosing strategies vary between trials, but many studies use weight-based dosing and adjust based on patient response. Some trials are specifically designed to determine the optimal dose for different patient populations or clinical scenarios, such as preventing fasciculations or achieving specific levels of neuromuscular blockade.
  • What are some of the key outcomes being measured in Cisatracurium Besilate trials? Key outcomes being measured include mortality rates, duration of mechanical ventilation, length of hospital stay, changes in intracranial pressure, respiratory mechanics (such as transpulmonary pressure), and the drug's pharmacokinetic and pharmacodynamic properties in critically ill patients.

Ongoing Clinical Trials on Cisatracurium Besilate

  • Study on the Effectiveness of Sphenopalatine Ganglion Block vs. Scalp Block in Patients Undergoing Craniotomy for Supratentorial Mass Using Levobupivacaine and Drug Combination

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium

  • A Study of Inhaled Sevoflurane Compared to Standard Intravenous Sedation (Dexmedetomidine, Midazolam, or Propofol) in ICU Patients at Risk of Acute Respiratory Distress Syndrome

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Acute Respiratory Distress Syndrome (ARDS): A severe lung condition characterized by rapid onset of widespread inflammation in the lungs, leading to difficulty breathing and low oxygen levels in the blood.
  • Neuromuscular Blocking Agent (NMBA): A drug that causes paralysis of the skeletal muscles, often used during surgery or in critically ill patients to facilitate mechanical ventilation.
  • Intracranial Hypertension: A condition where the pressure inside the skull is higher than normal, which can be dangerous for brain function.
  • Fasciculations: Small, involuntary muscle twitches or contractions that can be visible under the skin.
  • Barotrauma: Injury to the lungs caused by rapid or excessive changes in air pressure, often associated with mechanical ventilation.
  • Train-of-Four (TOF): A method used to monitor the degree of neuromuscular blockade by applying four electrical stimuli and measuring the muscle response.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.
  • Transpulmonary Pressure: The difference between the pressure in the alveoli (air sacs in the lungs) and the pressure in the space around the lungs, important for assessing lung mechanics.
  • Lung-Protective Ventilation: A strategy of mechanical ventilation designed to minimize lung injury by using lower tidal volumes and appropriate levels of positive end-expiratory pressure (PEEP).

References

  1. https://clinicaltrials.gov/study/NCT03337373
  2. https://clinicaltrials.gov/study/NCT00299650
  3. https://clinicaltrials.gov/study/NCT02481193
  4. https://clinicaltrials.gov/study/NCT02404779
  5. https://clinicaltrials.gov/study/NCT05760976
  6. https://clinicaltrials.gov/study/NCT06514209
  7. https://clinicaltrials.gov/study/NCT03831815